AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 302 min read$ALNY

What Just Happened To Alnylam Stock?

Alnylam Pharmaceuticals (ALNY) stock dropped 25.1% on October 29, 2026, despite beating Q3 revenue estimates. Management expressed dissatisfaction with demand growth, lowering TTR product sales guidance. Product revenue grew 52% YoY, led by AMVUTTRA. The stock's decline was independent of sector and market trends.

Original reporting
finance.yahoo.com
Published Oct 30, 2026, 4:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 5:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Just Happened To Alnylam Stock? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ALNYBearishHigh
01

Why it matters

The earnings release highlighted a revenue beat but a cautious demand outlook, prompting a steep price drop despite sector strength.

02

Market read

Company‑specific earnings news with material price impact; peers performed positively, underscoring isolated risk.

03

What to watch

Potential upside from upcoming 2027 guidance and pipeline progress not reflected in the immediate reaction.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Alnylam is a leading RNA‑interference therapeutics company; its TTR product portfolio drives the majority of revenue.

Company-level read

Ticker impact

$ALNYBearishHigh confidence
Context

Alnylam reported Q3 results that beat revenue estimates but warned demand growth is insufficient, causing a 25.1% share drop.

Expected impact

likely continued pressure as investors reassess demand outlook and lower guidance expectations

Evidence & confidence

The earnings release introduced new guidance shortfall and highlighted slower prescriber adoption, which directly triggered the large price decline.

Market effects

Sector

Health‑care sector shows resilience; peers rose, indicating the drop is company‑specific.

Regional

U.S. market impact limited to Alnylam; broader indices slipped modestly.

Global

Limited to biotech investors tracking RNA‑based therapeutics.

Counterpoint

What could challenge this read

The stock may be oversold after a sharp decline; demand concerns could be temporary.

Key entities

  • company
    Alnylam Pharmaceuticals

    Biotech firm reporting Q3 results.

Read at source← All news

StoryAlnylam Q3 2026 earnings beat but shares tumble as demand growth stalls and guidance trimmed

Also covered by

4 outlets

Related articles

NOV 3
$ALNYMed

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

Alnylam will present five-year data from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) at AHA and ISA 2026, showing long-term benefits in treating transthyretin amyloidosis (ATTR). The study includes open-label extension data and post hoc analyses demonstrating preserved exercise capacity and cardiopulmonary performance. Additional real-world evidence and comparisons with other treatments will also be presented.

stocktitan.net2 min
NOV 2
$AZNMed

Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience

AstraZeneca (AZN) reiterated its $80B revenue target by 2030, announced a $1.5B cost-savings program, and shares rose 7%. Alnylam (ALNY) reported $1.13B Amvuttra revenue, but shares fell 20% due to concerns over Medicare reimbursement and insurer policies. Regeneron (REGN) saw shares rise 13% after reporting record sales for Dupixent, Eylea, and Libtayo, beating expectations.

finance.yahoo.com7 min
OCT 30
$ALNYHigh

Raymond James cuts Alnylam stock rating on Amvuttra uncertainty

Raymond James downgraded Alnylam Pharmaceuticals (ALNY) to Outperform from Strong Buy, lowering its price target to $315 from $420. The move follows Alnylam's Q3 2026 results, citing uncertainty around Amvuttra's near-term trends. The stock has dropped 22% in a week, trading near its 52-week low. Despite beating earnings estimates, concerns about softer guidance and commercial delays led to the downgrade. Stifel also downgraded ALNY to Hold, reducing its price target to $225.

investing.com2 min
OCT 29
$ALNYMed

Alnylam Pharmaceuticals Inc (ALNY) (Q3 2026) Earnings Call Highlights: TTR Franchise Surges

Alnylam Pharmaceuticals (ALNY) reported Q3 2026 earnings, highlighting a 59% surge in TTR franchise but noting challenges. AMVUTRA demand growth lagged, and Q4 headwinds are expected due to inventory, pricing, and 340B rule uncertainty. The company delayed 2027 guidance. Management discussed strategies to address demand growth hurdles and potential 340B impacts. Key events, including data releases and clinical development updates, were outlined.

finance.yahoo.com7 min
OCT 29
$ALNYMed

Alnylam Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Alnylam Pharmaceuticals reported Q3 2026 revenue growth of 52% YoY to $1.3B, driven by AMVUTTRA. Management noted challenges in new patient starts despite sales force expansion. The company expects 2026 TTR product sales at the low end of $4.2B-$4.5B range. Positive interim results for brezosiran support a 2027 pivotal study. A $1.9B non-cash tax benefit was achieved. Guidance for 2027 revenues will be delayed to February 2027 due to regulatory uncertainties.

finance.yahoo.com7 min